Latachimo Combination

Per mL Latanoprost 50 mcg, timolol (as maleate) 5 mg

Reduction of IOP in patients w/ open angle glaucoma & ocular HTN who are insufficiently responsive to topical β-blockers or prostaglandin analogues.

One drop in the affected eye once daily. Max: Once daily.

Hypersensitivity. Active or history of bronchial asthma, bronchospasm & severe COPD; poorly controlled heart failure, sinus bradycardia & 2nd or 3rd-degree AV block & cardiogenic shock.

Patients w/ right heart failure due to pulmonary HTN; CHF; diabetic ketoacidosis or metabolic acidosis; poorly controlled diabetes; intraocular inflammation (iritis/uveitis); angle-closure glaucoma; patients potentially w/ latent herpes virus infection; aphakic & pseudophakic patients w/ torn posterior lens cap. May induce or exacerbate asthmatic attack. -ve chronotropic/inotropic effects. May exacerbate reduction of myocardial contractile force. May mask symptoms of hypoglycemia. Reports of macular edema, including cystoid macular edema & decreased visual acuity associated w/ macular edema; elevated IOP; herpetic keratitis. May be absorbed systemically & may cause an adverse reaction similar to that caused by systemic administration of β-blockers. Risk of iris pigmentation; corneal epithelium disorder. Refractive adjustments may be required when switching from miotic to timolol maleate prep due to the disappearance of miotic action. Administer at least 5 min apart if to be used w/ other ophth soln. Contains benzalkonium Cl; remove contact lenses before installation & may be reinserted after ≥15 min. More frequent administration may decrease IOP lowering effect. Blurred vision may temporarily occur after administration; refrain from operating machinery or driving a car until symptoms disappear. Should be used in pregnant women or women who may be pregnant only if expected therapeutic benefits outweigh possible risks. Avoid administration to nursing mothers. Safety in ped patients has not been established. Caution in elderly patients.

Iris pigmentation; ocular pemphigoid; bronchospasm, dyspnoea & resp failure; cardiac block/failure/arrest, cerebral ischemia & cerebrovascular disorder; SLE.

Reports of enhanced mydriatic action w/ adrenaline & dipivefrin HCl. Risk of excessive sympathetic nervous system suppression, hypotension & bradycardia w/ catecholamine-depleting drugs (eg, reserpine). Risk of enhanced reduction in IOP or β-blocker systemic effect w/ systemically administered β-blockers (eg, atenolol, propranolol HCl, metoprolol tartrate). Risk of AV block, left ventricular failure & hypotension w/ Ca antagonists (eg, verapamil HCl, diltiazem HCl). Enhanced inhibition of cardiac conduction w/ digitalis prep (eg, digoxin, digitoxin). Reports of enhanced β-blocking activity (eg, decreased heart rate, bradycardia) w/ CYP2D6 inhibitors (eg, quinidine sulfate hydrate, SSRIs). Reports of elevated IOP w/ ophth prostaglandin analogues (eg, isopropyl unoprostone, bimatoprost).

Antiglaucoma Preparations

S01ED51 - timolol, combinations ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.

P₁S₁S₃